共 50 条
- [1] Cost savings of conversion from filgrastim or pegfilgrastim to biosimilar filgrastim-sndz for chemotherapy-induced (febrile) neutropenia (CIN/FN) prophylaxis and expanded access to biosimilar GCSF on a budget neutral basis.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35McBride, AliAbraham, IvoMacDonald, KarenCampbell, KimBikkina, MohanBalu, Sanjeev
- [2] EXPANDED ACCESS TO PEMBROLIZUMAB FROM COST-SAVINGS GENERATED BY BIOSIMILAR FILGRASTIM (BIOSIM-FIL) IN THE PROPHYLAXIS OF CHEMOTHERAPY-INDUCED (FEBRILE) NEUTROPENIA (CIN/FN): SIMULATION STUDYVALUE IN HEALTH, 2017, 20 (09) : A443 - A443McBride, A.Balu, S.Campbell, K.Bikkina, M.MacDonald, K.Abraham, I
- [3] Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndzFUTURE ONCOLOGY, 2017, 13 (25) : 2285 - 2295McBride, AliBalu, SanjeevCampbell, KimBikkina, MohanMacDonald, KarenAbraham, Ivo
- [4] Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropeniaJOURNAL OF MEDICAL ECONOMICS, 2017, 20 (10) : 1083 - 1093McBride, AliCampbell, KimBikkina, MohanMacDonald, KarenAbraham, IvoBalu, Sanjeev
- [5] Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropeniaJOURNAL OF MEDICAL ECONOMICS, 2018, 21 (06) : 606 - 609McBride, AliCampbell, KimBikkina, MohanMacDonald, KarenAbraham, IvoBalu, Sanjeev
- [6] Simulation modeling of cost-savings from conversion of pegfilgrastim to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) and expanded access to biosimilar prophylaxis.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)McBride, AliMacDonald, KarenAbraham, Ivo
- [7] Potential Cost Savings From Chemotherapy-Induced Febrile Neutropenia With Biosimilar Filgrastim and Expanded Access to Targeted Antineoplastic Treatment Across the European Union G5 Countries: A Simulation StudyCLINICAL THERAPEUTICS, 2015, 37 (04) : 842 - 857Sun, DianaAndayani, Tri MurtiAltyar, AhmedMacDonald, KarenAbraham, Ivo
- [8] Simulation Modeling of Cost-Savings from Conversion to Biosimilar Pegfilgrastim-Cbqv for the Prophylaxis of Chemotherapy-Induced Neutropenia, and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy from Derived Cost-Savings in Non-Hodgkin LymphomaBLOOD, 2020, 136McBride, AliMacDonald, KarenAbraham, Ivo
- [9] Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqvJOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1466 - 1476MacDonald, KarenMcBride, AliAlrawashdh, NedaAbraham, Ivo
- [10] Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)Li, Edward C.Mezzio, DylanCampbell, Kimberley J.Spargo, AndrewLyman, Gary H.